Overview

A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease

Status:
Completed
Trial end date:
2019-12-17
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.
Phase:
Phase 2
Details
Lead Sponsor:
Alkahest, Inc.